Compare OII & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | BEAM |
|---|---|---|
| Founded | 1964 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | OII | BEAM |
|---|---|---|
| Price | $24.68 | $24.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $25.00 | ★ $48.09 |
| AVG Volume (30 Days) | 744.0K | ★ 2.2M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | $55,701,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $1.81 | $19.01 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | ★ 8.71 | N/A |
| 52 Week Low | $15.46 | $13.53 |
| 52 Week High | $30.98 | $35.25 |
| Indicator | OII | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 52.36 |
| Support Level | $22.77 | $20.23 |
| Resistance Level | $24.95 | $25.56 |
| Average True Range (ATR) | 0.74 | 1.61 |
| MACD | 0.14 | 0.41 |
| Stochastic Oscillator | 85.07 | 72.11 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.